FDA Approval Remains Pending For Intellia Therapeutics' Treatment As Stock Plunges 8% After Clinical Update
Coverage and center readiness would determine whether the launch plan's envisioned wait of three to six months between potential approval and first treatments and revenue holds.
Intellia Therapeutics, which develops gene-editing treatments, plunged 8.1% to $9.70 at Friday's close, erasing $119 million in market value after Thursday's clinical update. Its experimental treatment for recurring swelling attacks remains awaiting FDA approval.
Fewer Attacks, Infusion Reactions
Intellia presented the update on lonvoguran ziclumeran, known as lonvo-z, with an SEC filing Thursday. The treatment targets hereditary angioedema, a disorder that causes painful swelling that can become dangerous.
Compared with the monthly attack frequency recorded during their previous preventive treatment, the 35 recipients in the late-stage trial experienced 81% fewer attacks per month. Across 93 people given the 50-milligram dose, 51 had infusion reactions.
Potential approval would be followed by a wait of three to six months before first treatments and revenue under Intellia's illustrative launch plan. Insurance coverage and treatment centers' readiness would determine whether the company begins treating patients within that window.
A Single-Infusion Gene-Editing Bet
Intellia uses CRISPR, a technology for changing DNA, to develop treatments for severe diseases. Its lead experimental programs are designed to be given through a single intravenous infusion and are in late-stage clinical development.
Alongside lonvo-z, Intellia is developing nexiguran ziclumeran for transthyretin amyloidosis, which harms organs and tissues through protein buildup. Partner Regeneron shares approximately 25% of worldwide development costs and commercial profits for that program.
Intellia runs studies across multiple countries and develops treatments both independently and with partners. Its technology-licensing arrangements include payments, royalties and shared costs.
Safety scrutiny has affected other Intellia programs. The FDA stopped two studies last year after a participant suffered liver damage and died; it lifted those holds this year with additional safeguards.
A Month Of Sharp Drops
Friday's decline left Intellia with a market value of about $1.4 billion. The original report described the stock as on pace for its fourth decline of 7% or more this month.
At Thursday's close, shares were up 17% year-to-date, compared with an 11% gain for the S&P 500. Intellia had nevertheless fallen 16% over the previous month.
In its earlier quarterly filing, Intellia reported revenue of $7.2 million, down 48% from a year earlier, and a $127.5 million net loss.
Saturday's scheduled presentations will cover lonvo-z's four-year safety and durability results, including whether patients remain free of attacks without preventive medication.
Sources
- Novel CRISPR therapy is poised to gain first FDA approval to alter genes inside the body | Nature — nature.com
- Intellia Therapeutics Presents Additional Positive Clinical — globenewswire.com
- The company's filing (Intellia Therapeutics) — SEC filing
- Intellia Therapeutics — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR